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ABSTRACT 
Objective. Aberrant activation of synovial fibroblasts (SFs) is a key determinant in 
the pathogenesis of rheumatoid arthritis (RA). We aimed to produce a map of gene 
expression and epigenetic changes occurring in this cell type during disease 
progression in the human TNF-transgenic model of arthritis, and identify 
commonalities with human SFs. 
Methods. We used deep sequencing to probe the transcriptome, the methylome 
and the chromatin landscape of cultured mouse arthritogenic SFs at three stages of 
disease, as well as SFs stimulated with human TNF. We performed bioinformatics 
analyses at the gene, pathway and network levels, compared mouse and human 
data, and validated selected genes in both species.  
Results. We report that SF arthritogenicity is reflected on distinct dynamic patterns 
of transcriptional deregulation, enriched in pathways of the innate immune 
response and mesenchymal differentiation. A functionally-representative subset of 
these changes is associated with methylation, mostly in gene bodies. The 
arthritogenic state involves highly active promoters, marked by H3K4 
trimethylation. There is significant overlap between mouse and human data, at the 
level of deregulated genes and to an even higher extent at the level of pathways. 
Conclusion. This work presents the first systematic examination of the pathogenic 
changes that occur in mouse synovial fibroblasts in progressive TNF-driven 
arthritogenesis. Significant correlations with respective human RA SF data further 
validate the human TNF-transgenic mouse as a reliable model of the human 
disease. The resource of data generated here may serve as a framework for the 
discovery of novel pathogenic mechanisms and disease biomarkers.  
This article is protected by copyright. All rights reserved.
Genomic alignments of mouse and human arthritogenic synovial fibroblasts. 
4 
 
Rheumatoid arthritis (RA) is a chronic, inflammatory, disease, characterised by 
extensive damage to diarthroidal joints. Our understanding of RA has largely relied 
on the use of mouse models, such as collagen-induced arthritis, collagen antibody-
induced arthritis and the TNF-transgenic models; work on the latter established the 
proof of principle for the pivotal role of TNF in disease pathogenesis and its 
therapeutic targeting by anti-TNF biologics (1). The same models established the 
synovial fibroblast (SF) as a key cellular player and target of TNF in RA (2). Whilst 
under physiological conditions SFs provide nourishment and protection to the joint, 
upon chronic innate immune activation, they undergo a complex process described 
as arthritogenic “transformation”: they proliferate aberrantly and acquire resistance 
to death, thus becoming hyperplastic; and they express pro-inflammatory cytokines, 
matrix degrading enzymes and cell adhesion molecules, thus contributing to an 
inflammatory and tissue-damaging microenvironment  (3–5). Moreover, SFs can 
migrate to distant sites via the vasculature, maintaining and transferring their newly-
acquired destructive properties, both in human and in mouse models (6,7).  
Epigenetic changes underlie the activated and aggressive phenotype of RA SFs (8). 
Most of the relevant studies have examined the contribution of the methylome, 
reporting global genomic hypo-methylation in the arthritogenic human synovial 
fibroblast (9–12). In addition, micro RNA deregulations are known to accompany 
disease both in human and mouse (13).  
In order to assess the gene expression and epigenetic changes that occur in synovial 
fibroblasts during the arthritogenic process, we have initiated a multi-level omics 
analysis of human TNF-transgenic (Tg197) SFs using next generation sequencing 
(NGS) approaches. Here, we report the molecular profile of the activated synovial 
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fibroblast at the level of the transcriptome, the methylome and active chromatin as 
evidenced by H3K4 trimethylation. This profile entails distinct deregulations 
associated with functional pathways, notably related to the innate immune response 
and mesenchymal differentiation; methylation changes correlated with expression in 
specific genes; and an activated chromatin profile. In the context of this key 
pathogenic cell type, at the level of genes and even more at the level of pathways, 
the human TNF-transgenic model aligned significantly with human data. 
 
MATERIALS AND METHODS 
 
Mouse and human synovial fibroblasts 
Mouse synovial fibroblasts were isolated from CBAxC57BL/6 human TNF-transgenic 
(TghuTNF; Tg197) mice (1) and wild-type littermates housed under specific 
pathogen-free conditions at three disease stages: early (3 weeks), established (8 
weeks) and late (11 weeks), as previously described (14). Three biological replicates 
were isolated per condition; for each, a pool of three mixed-gender mice was used.  
Purity of all isolations was assessed by FACS, with acceptance criteria being: more 
than 85% positive for CD90.2 and less than 2.5% positive for CD45. 
Human samples used for RNA sequencing were isolated from the knees of three RA 
patients, as well as of three healthy individuals (as defined below), as detailed 
elsewhere (15). Human RA synovial fibroblasts used for validations were isolated 
from synovial tissues obtained from patients undergoing joint replacement surgery 
at the Schulthess Clinic, Zurich, Switzerland. All patients fulfilled the 2010 
ACR/EULAR criteria for the classification of RA. Samples described as healthy synovial 
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fibroblasts were grown from synovial biopsies from arthralgia patients without 
clinical or histological signs of inflammation or cartilage destruction, at the Queen 
Elizabeth Hospital, Birmingham, UK. Details regarding these human samples can be 
found in Supplementary Table 1. Human studies were approved by the local ethics 
committees of the University Hospital Zurich, Switzerland and the University of 
Birmingham, UK. Informed consents were obtained from all patients. 
 
Extraction of RNA and DNA  
RNA was extracted from mouse SFs using the Absolutely RNA Miniprep Kit (Agilent 
Technologies) and from human SFs using the miRNeasy Mini kit (Qiagen). DNA was 
extracted from mouse SFs using the PureLink Genomic DNA Mini Kit (Invitrogen).  
 
Enrichment for MethylCap and H3K4me3 
In order to enrich for methylated DNA, the MethylMiner DNA Enrichment Kit from 
Invitrogen was used as per the manufacturer’s instructions. DNA was firstly 
fragmented by sonication to an average size of 250 bp using a Covaris S220 focused-
ultrasonicator. Then enrichment was performed with a double elution (high and low 
salt) in order to capture both sparsely- and densely-methylated DNA; fractions were 
combined in the end. To enrich for H3K4me3, DNA was processed using the iDeal 
ChIP-seq Kit (Diagenode) in combination with a ChIP-grade H3K4me3 antibody 
(Diagenode), as per the manufacturer’s instructions. Chromatin was firstly sheared 
by sonication using a Bioruptor (Diagenode) and then subjected to the H3K4me3 
enrichment protocol with a minor modification: after performing an RNase I 
digestion for 30 min at 37oC, the de-crosslinked DNA was eluted using the QIAquick 
This article is protected by copyright. All rights reserved.
Genomic alignments of mouse and human arthritogenic synovial fibroblasts. 
7 
 
PCR Purification Kit (Qiagen). Enrichment (in comparison to a non-enriched input 
control) was confirmed by quantitative PCR.  
 
Preparation of libraries and next generation sequencing 
All library preparations, next generation sequencing and quality control steps were 
performed by the McGill University and Genome Quebec Innovation Centre. More 
specifically, for RNA-seq, TruSeq RNA libraries were prepared and samples were run 
in an Illumina HiSeq2000 platform using a 100 bp paired-end setup. For MethylCap-
seq, TruSeq genomic DNA libraries were prepared and samples were run in an 
Illumina HiSeq platform using a 100 bp paired-end setup. For ChIP-seq, TruSeq 
genomic DNA libraries were prepared and samples were run in an Illumina HiSeq 
platform using a 100 bp paired-end setup. For human samples, preparation of 
libraries and next generation sequencing was performed as detailed elsewhere (15)  
 
Bioinformatic analyses 
General: Quality of sequencing was accessed using FastQC software (16), which also 
calculates the average quality of reads. The number of mapped reads was calculated 
with the use of the samtools tool (-flagstat) (17). Conversion of alignment files (bam) 
to bed format was done with bedtools (bamtobed) (18). Bam files were also 
converted to bedgraph with bedtools (genomecov -bga) and bedgraph files were 
converted to bigwig using the UCSC bedGraphToBigWig utility. Volcano plots were 
created in R with an in-house developed script, which is based on the ggplot 
package. Heat maps were also generated in R with the heatmap.2 function of the 
gplots package. Functional analyses were performed with the online tool Enrichr 
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(19). For all statistical comparisons the cut-off for significance was set to 0.05. With 
the exception of KEGG pathway enrichment and human RNA-seq analyses, in all 
other comparisons p values were adjusted for multiple comparisons. Human-mouse 
overlap was tested using an online tool based on a normal approximation to the 
exact hypergeometric probability  (20).  
RNA-seq: Mouse RNA-seq samples were analysed with the tophat-cufflinks pipeline 
(21–23). Reads were mapped to the mm9 genome with tophat2. Transcripts were 
assembled using cufflinks. Final transcriptome assembly was performed with 
cuffmerge and differential expression was identified with cuffdiff. Venn diagrams 
were created with InteractiVenn (24) or the online tool Venny (25). Clustering of 
genes was performed with k means based on both the fold change and the q value of 
all time points. The number of clusters was selected with the use of the elbow rule. 
The average cluster profile was plotted in R using the fold changes and the q values 
of the clusters' centroids. RNEA was performed as previously described  (26). 
Networks were visualised in Cytoscape (27) and the characteristics of nodes (colour 
and size) were based on betweenness centrality and outdegree. The compilation of 
differentially-expressed gene lists from human RNA sequencing data has been 
described elsewhere (15). 
 
MethylCap-seq/H3K4me3-seq: MethylCap- and H3K4me3-seq reads were mapped 
using the BWA tool (28). Visualisations of general profiles were created with seqplots 
(29). Methylation plots were generated with the use of a pseudo-length of 10 kb, to 
which the genes were extended or shrunk using linear approximation (“anchored 
features”). Differential analysis was performed with diffReps (30) using the default 
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normalisation procedure and windows of 500 bases for MethylCap-seq and 1000 
bases for H3K4me3-seq.  
 
Quantitative RT-PCR 
For validation of deregulated genes identified by RNA-seq in the mouse, an 
independent set of mouse SF RNA was used, comprising triplicate biological samples 
for each condition. All primers were QuantiTect Primer Assays (Qiagen) and were 
used in conjunction with QuantiFast SYBR Green RT-PCR Kit (Qiagen), according to 
the manufacturer’s instructions. Thermal cycling was performed in a Bio-rad CFX96 
Touch Real-Time PCR Detection System. Expression was quantified relative to B2m. 
For validations in human SFs, reverse-transcribed total RNA was measured in a 7500 
Real-Time PCR System (Applied Biosystems) using self-designed primers (Suppl. 
Table 2) in combination with SYBR green dye. No template control samples, 
dissociation curves and samples containing the non-transcribed RNA were run as 
controls. For normalisation, expression of HPRT1 was used (target – HPRT1 
expression = ΔCT). 
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RESULTS 
 
Arthritogenic synovial fibroblasts from the Tg197 mouse exhibit distinct patterns of 
transcriptional deregulation during disease progression. 
In order to explore cell-specific transcriptional changes accompanying disease 
progression in the Tg197 mouse model of rheumatoid arthritis, synovial fibroblasts 
were isolated from diseased and healthy animals at three stages of disease: 3 weeks, 
representing an early stage of not overtly manifested pathology; 8 weeks, which is a 
stage of established disease; and 11 weeks, a late stage of severe pathology (Suppl. 
Figs. 1 and 2A). RNA samples were processed for NGS, confirming the quality of 
sequencing as shown in Supplementary Figures 2B and C. As can be seen in Figure 
1A, more than one thousand significant differentially-expressed genes (DEGs) were 
identified. The early stage of disease is characterised by the least, equally 
represented by up- and down-regulation, whereas the most were identified in the 
established stage, where up-regulation predominates; this is also true for the late 
stage of disease. A considerable number of DEGs are persistent throughout disease 
(177 up-regulated; 114 down-regulated), while there are also stage-specific ones 
(Fig. 1B). Interestingly, the vast majority of early DEGs are met throughout the 
disease, indicating genes that play a central role in disease development.  
In an effort to explore further the patterns of deregulation identified, we classified 
DEGs in six clusters, according to their occurrence in disease progression (Fig. 1C). 
Three clusters were associated with up-regulated genes and three with down-
regulated genes. These clusters were then subjected to functional enrichment 
analysis, so as to examine whether they are associated with distinct functional 
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categories. Regarding up-regulation clusters, immune response was identified as the 
most prominent functional category, being significant throughout disease 
progression. Stage-specific up-regulation encompasses functions of cell signalling, 
cell adhesion, cytokine response, cell motility and the extracellular matrix. Notably, 
genes down-regulated in all disease stages are functionally related to differentiation. 
This becomes more pronounced in the cluster of genes down-regulated at the late 
stage, where we observed a deficit in the culmination of differentiation processes 
(termed morphogenesis). Additional functions of down-regulation across disease are 
related to the extracellular matrix and negative regulation of proliferation (hence an 
overall positive proliferative potential). Stage-specific down-regulation clusters 
include functions of cell division and regulation of WNT signalling. In the context of 
all these clusters, late is the most distant hierarchically, indicating the farthest, 
functionally evolved, stage of disease. 
In a complementary functional approach, the deregulation of each disease stage was 
subjected to functional enrichment and clustering was performed according to the 
top 25 terms of the early stage (Fig. 1D). Functions enriched in the up-regulated 
genes mostly correspond to the immune response and their enrichment becomes 
more pronounced with disease progression. The majority of the top immune 
response-related ontology terms enriched in the three stages are related to the 
innate immune response and TLR signalling. Functions enriched in the down-
regulated genes are mostly linked to differentiation and the extracellular matrix; the 
tendency across disease applies here too, albeit to a lesser extent. As in the first 
functional analysis, the late stage of disease is the most distant one. 
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In addition, we sought to identify transcriptional regulators that underlie the 
identified deregulation profiles. To this end, an in-house developed tool, RNEA, was 
used, which performs enrichment analysis using transcriptomic data in combination 
with transcriptional network assignment algorithms (26). Having observed that 
despite the high complexity of networks derived for each disease stage the top 
significant central players were consistent (Suppl. Fig. 3), we focused on the common 
transcriptional network that applies throughout disease. As can be seen in Figure 1E, 
this transcriptional network was found to have three central regulators: NFKB1, 
PPARG and CEBPA. These transcription factors are highlighted to have both a central 
and strong impact, placing the NF-κΒ and mesenchymal differentiation pathways in 
the core of our transcriptome profiles and thus Tg197 pathogenesis.  
 
Global DNA methylation changes associate with the activated Tg197 SF profile. 
We next examined the methylome of the arthritogenic synovial fibroblast. 
MethylCap sequencing was performed using the same biological sample set; quality 
control metrics can be seen in Supplementary Figures 2B and C. Approaching 
differential methylation using a promoter/gene body dichotomy in our analyses, we 
observed that in the early and late stage promoters, differentially-methylated 
regions (DMRs) show similar levels of enrichment (hyper-) and depletion (hypo-
methylation; Fig. 2A). In the established stage, there is a tendency for more hyper-
methylation. As regards gene body methylation, there is pronounced hypo-
methylation associated with the established stage of disease. Looking into the 
distribution of these DNA methylation changes, as disease progresses the signal 
tends to spread away from the transcription start site (Fig 2B). There is a higher 
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enrichment in gene body methylation, most of which being exonic, while most 
overall differential methylation is found in CpG islands.  
As to the relationship between DNA methylation and expression, we firstly noted 
that if we stratify our expression data in quantiles then methylation appears to be an 
indicator of the level of expression, positively downstream of the transcription start 
site, mostly negatively upstream of it (Fig. 2C). Trying to correlate the deregulations 
identified at the RNA level with changes in DNA methylation, we observed that 
approximately one quarter of our DEGs at any disease stage are accompanied by a 
change in methylation (Fig. 2D). Out of these, half follow the “canonical” correlation 
between methylation and expression (inverse for the promoter, positive for the gene 
body), the vast majority of which corresponding to gene body DMRs. Approximately 
one fifth of the latter, i.e. of genes whose deregulation at the RNA level is positively 
correlated with gene body methylation,  are associated with exonic DMRs. 
We then narrowed down our analysis to the genes that are both differentially-
expressed and methylated in the expected manner and performed functional 
enrichment. This approach returned functions most significantly related, at all 
stages, to the extracellular matrix and, at the established and late stages, to cytokine 
signalling, proliferation, adhesion, migration, differentiation, and cell death. These 
enrichments constitute a representative subset of the above-described functional 
profile based on the RNA-seq data.  
These results suggest that DNA methylation accompanies a subset of functionally-
important, disease-associated deregulation in the Tg197 mouse.  
 
Activation of the synovial fibroblast is marked by open chromatin. 
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To assess transcriptionally-active genes, we probed for H3K4 trimethylation, a 
histone mark associated with active promoters. Quality control metrics of the 
sequencing can be found in Supplementary Figure 2. Most differentially-marked 
regions were identified in the early time-point, where H3K4me3 depletion 
predominates, whereas in the other two time-points there are approximately equal 
numbers of enriched and depleted regions (Fig. 3A). Inspecting the distribution of 
changes, we observed that in all three time-points there is enrichment in the 
promoter, as expected for this histone mark, without any clear differences in 
distance to the transcription start site (TSS; Fig. 3B). Focusing therefore around the 
TSS, we noted that H3K4me3 signal mirrors the level of expression, both of the 
Tg197 and the wild-type (Fig. 3C). Interestingly, the activated state of the arthritic SF 
is evident in this marker of open chromatin both at the early and the established 
stage, as Tg197 H3K4 trimethylation levels are higher overall. Significant H3K4 
trimethylation in the synovial fibroblast was hence found to be a good predictor of 
differential expression: the correlation between H3K4me3 and RNA expression is 
high for all disease stages (rs = 0.69 for the early, 0.61 for the established and 0.72 
for the late time-point; Fig. 3D). Due to this high correlation, the output of functional 
enrichment analysis of differentially H3K4-marked and expressed genes mirrors that 
of the general profile (data not shown).  
Based on the above, pathogenic activation of the synovial fibroblast is engraved on 
its chromatin, with H3K4 trimethylation being a good marker for this activation. 
 
Assessment of the impact of exogenously-administered TNF on the identified 
signatures. 
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TNF plays a pivotal role in both Tg197 and human disease, where it is a major 
pathogenic cytokine in the inflammatory milieu of the arthritic joint (1). We aimed to 
assess the ex vivo impact of TNF at the level of the transcriptome, methylome and 
active chromatin, so as to build on our understanding of the interplay of TNF and 
synovial fibroblast biology, also given that TNF stimulation is widely used in human 
RA SF studies. To this end, in parallel to our above efforts, wild-type SFs were treated 
with human TNF for 24 hours and analysed as the rest of the samples (see Suppl. Fig. 
1 for sequencing metrics). Figure 4A summarises our findings of genes up- or down-
regulated at the level of RNA, hyper- or hypo-methylated, and enriched or depleted 
in H3K4me3, following stimulation with human TNF. 
At the level of differentially-expressed genes or differentially-marked regions, a 
considerable number of deregulations forming part of the Tg197 signature are 
shared with the TNF-induced profiles in all three time-points: approximately 85% for 
RNA and DNA methylation and 70% for H3K4 trimethylation (Fig. 4B). At the level of 
pathways, the overlap becomes more pronounced, where we observed that sixteen 
out of twenty KEGG pathways enriched following TNF stimulation were also found in 
the Tg197 signatures. Nonetheless, a high number of significant DEGs (100 for the 
early, 718 for the established and 554 for the late stage) and enriched pathways (1, 
18 and 18, respectively), were only identified in the Tg197 profiles. 
It follows from the above that, ex vivo as in vivo, TNF sensed by the synovial 
fibroblast contributes to the creation of a pro-inflammatory and pathogenic 
environment that is reflected, at the level of both genes and pathways, on 
pathogenic changes to the transcriptome, the methylome and chromatin.  
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Validations and comparisons with human data. 
In a technical validation of our sequencing results, a panel of 20 genes selected 
among the top deregulated ones identified by RNA-seq were validated by 
quantitative RT-PCR (qRT-PCR), using an independent sample set. As can be seen in 
Figure 5A, there was a very high correlation between RNA-seq and qRT-PCR data, 
establishing experimental reliability (rs = 0.96 for the early, 0.90 for the established 
and 0.90 for the late time-point).  
To assess whether our findings in the mouse can be verified in the context of human 
disease, we made use of an RNA-seq data set comparing human RA SFs to healthy 
SFs. The broad picture of the identified human deregulations can be seen in Figure 
5B. At the level of genes, approximately a tenth of mouse SF deregulations were also 
identified in the same direction in the human, a very significant  overlap (p < 0.001), 
despite differences in isolation and culturing conditions, inter-species variability and 
the high inter-patient variability in humans (Fig. 5C). At the level of pathways, this 
significant overlap  becomes higher, with approximately one third of the pathways 
enriched in mouse SFs being also enriched in human SFs (p < 0.001); key pathways 
identified above, such as innate immune and differentiation pathways, were found 
to be shared. 
Eight genes that were validated in mouse SFs and represent key pathways, such as 
immune response and differentiation, shared by mouse and human, were also 
examined by qRT-PCR in human SFs (Fig. 5D). Five out of them were significantly 
deregulated in these samples, namely MMP3 (up-regulated), and LECT1, WNT16, 
PPARG and SP7 (down-regulated). NOD2 (an up-regulated DEG) was also found to 
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differ significantly upon TNF stimulation, as its baseline levels are very low in the 
human (data not shown).  
For a comparison between mouse and human at the level of the methylome, we 
exploited two studies reporting human SF data (9,31). We compared the intersection 
of changes reported by these studies with our mouse methylation data (Fig. 5E). As 
can be seen, approximately half of the genes identified in the human are also found 
in the mouse, a highly significant overlap (p < 0.001).   
Our findings contribute towards a systems-level validation of the human TNF-
transgenic mouse as a model of the human disease, highlighting cell type-specific 
commonalities in key genes and pathways. 
 
 
DISCUSSION 
In light of recent controversies on whether animal models accurately reflect human 
disease  (32,33), we re-approached one of the key mouse models of rheumatoid 
arthritis, the human TNF-transgenic mouse, so as to achieve a high-resolution profile 
of the activated synovial fibroblast and compare it to human disease. In this disease-
driving cell type, arthritogenicity is mirrored on distinct expression profiles 
characterised by early-onset and persistent changes, indicating that, even before the 
joint has been extensively damaged, pathogenic molecular processes are already at 
work.  
Functionally, continuous up-regulation of gene expression was connected with the 
innate immune response, highlighting the role of the synovial fibroblast as an innate 
immune sensor (34–36). Down-regulation was linked to functions related to cell 
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differentiation, with two out of the three identified central transcriptional 
regulators, namely CEBPA and PPARG, being involved in mesenchymal differentiation 
(37,38); the latter was also validated here in human RA SFs by quantitative RT-PCR. 
Given the unclear relationship between mesenchymal stem cells and RA SFs and the 
importance of differentiation processes in disease pathogenesis (39,40), the aspect 
of synovial fibroblast ontogeny in physiology and pathology merits further 
exploration and presents a good case of how omics data can be the starting point for 
more focused studies.  
To date, the most studied epigenetic change in RA has been DNA methylation. The 
examination of our data from the perspective of the gene body, which represents 
the majority of genic space, reveals a hypo-methylated profile, in agreement with 
previous publications in human RA SFs (12). Genome-wide correlations between 
DNA methylation and gene expression are hampered by the complexity of the 
former as an epigenetic phenomenon. Nevertheless, we have been able to link 
differential methylation, most abundantly at the gene body, with approximately a 
quarter of our identified expression changes. In concert with the above-described 
functional highlights, among the functions enriched in differentially-methylated and 
expressed genes, we also find highly significant examples of mesenchymal 
differentiation processes and the innate immune response. Sox10, through 
methylation-dependent transcription is implicated to suppress stemness by binding 
to beta catenin, and is also expressed by a novel rat synovial stem cell population 
capable to give rise to mesenchymal lineages (41,42).  Moreover, this is the first 
report of methylation-modulated expression of TLR2, a known innate immune 
sensing receptor in SFs, as observed in other inflammatory conditions (34,43).  It is 
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also the first time that increased expression of podoplanin (Pdpn), which is well-
documented in human arthritic synovium, is linked with changes in promoter 
methylation, similar to other cells of mesenchymal origin (44–46). 
Furthermore, this work represents the first attempt to explore H3K4 trimethylation 
in SFs. Their arthritogenicity was shown to be defined by activated chromatin, 
making the promoters of pathogenic genes highly active and ready to drive disease-
promoting transcription. Interestingly, in another innate immune cell type, the 
macrophage, it is known that TLR signalling induces H3K4 trimethylation so as to 
facilitate rapid transcription of target genes (47). This histone mark has also been 
reported to play a role in mesenchymal differentiation (48). Even if genome-wide 
experiments cannot resolve the causal link between histone modifications and gene 
expression changes, time-dependent approaches as the one presented here could 
provide the basis for more sophisticated models addressing this issue. 
Bioinformatic probing of the present Tg197 mouse RNA-seq data by functional 
enrichment analysis against the human-specific dbGaP database (49) revealed that 
the most significant term returned in all three disease stages is “rheumatoid 
arthritis”, a finding that, when combined with the overall high similarity between 
mouse and human data presented here, reinforces the value of this model. Despite 
its TNF dependency and the observed overlap between the Tg197 profiles and those 
identified upon human TNF treatment, the latter failed to include many gene 
deregulations, especially of the established and late stages of disease. More 
importantly, the mouse pathways that collectively account for the resemblance to 
human disease are significantly enriched only in the Tg197 profiles highlighting the 
importance of analyses deriving from in vivo contexts.  
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To our knowledge this is the first cell type-specific multi-level characterisation of a 
mouse model of RA in alignment with human disease. With our current findings, we 
posit that, rather than comparing mixed and often secondarily-activated material 
from animal models and humans, careful validation of primarily disease-associated 
cell types, such as SFs in RA, should be ensured before concluding that an animal 
model mimics or not the human disease and to what extent. The present 
compendium of data can serve as the foundation for a range of future studies: from 
the basic mechanistic investigation of disease pathogenesis to the translational 
examination of novel biomarkers and the preclinical testing of therapeutics through 
the comparative alignment of readouts against reference profiles presented in this 
work.  
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FIGURE LEGENDS 
 
Figure 1 Arthritogenic synovial fibroblasts are deregulated at the level of the 
transcriptome across disease stages in the Tg197 mouse model of RA. RNA-seq 
profile of Tg197 SFs as compared to wild-type (WT) controls at three different 
disease stages (early: 3 weeks; established: 8 weeks; and late: 11 weeks). FC = fold 
change; PV = corrected p value. (A) Volcano plots depicting differentially-expressed 
genes (DEGs) at the three stages of disease. (B) Venn diagrams showing overlap of 
significant DEGs among disease stages. (C) Heat map showing clustering of significant 
DEGs across disease stages. Genes were divided in six clusters, each showing a 
distinct pattern of deregulation as shown in the right hand-side graph. Functional 
analysis was performed for these clusters; shown (left) are descriptors summarising 
the top 10 gene ontology (biological process; GO-BP) terms (ranked by q value). (D) 
Heat map showing clustering of the top 25 (as ranked by q value) significant GO-BP 
terms associated with each disease stage. (E) The common transcriptional network 
of the three disease stages, as identified by RNEA. Colour bar indicates node 
centrality; circle size indicates number of edges from the node, i.e. number of 
targets. 
 
Figure 2 Global DNA methylation changes constitute part of the arthritogenic 
profile of the Tg197 synovial fibroblast. MethylCap-seq profile of Tg197 SFs as 
compared to WT controls at the three different disease stages. FC = fold change; PV 
= corrected p value. (A) Volcano plots depicting differentially-methylated regions 
(DMRs) at the three stages of disease in either promoters or gene bodies. (B) 
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Distribution of significant DMRs in promoters and gene regions, as well as in relation 
to CpG islands, across disease stages. y axes represent relative enrichment; CGI: CpG 
island. (C) Expression data of the three disease stages displayed in four quantiles 
against DNA methylation signal around the transcription start site (TSS) up to the 
transcription stop site (TES).  (D) Pie charts showing percentages of significant DEGs 
that are also significantly differentially-methylated (DM) in each disease stage.  
Expected DM = expression correlated positively with gene body or inversely with 
promoter methylation. 
 
Figure 3 Activated synovial fibroblasts are characterised by the presence of 
open chromatin. H3K4me3-seq profile of Tg197 SFs as compared to WT controls at 
the three different disease stages. FC = fold change; PV = corrected p value. (A) 
Volcano plots depicting differentially H3K4-trimethylated regions in promoters at the 
three stages of disease. (B) Distribution of significant differentially H3K4-
trimethylated regions in promoters, across disease stages. (C) Expression data 
displayed in four quantiles against H3K4me3 signal around the transcription start site 
(TSS).  (D) Scatter plots showing correlation between significant H3K4 trimethylation 
(y axis) and expression (x axis).  
 
Figure 4 TNF has a pronounced contribution in the identified signatures of the 
Tg197 synovial fibroblast. RNA-seq, MethylCap-seq and H3K4me3-seq were 
performed in WT SFs treated with 10 ng/ml human TNF for 24 h and compared to 
the untreated controls. FC = fold change; PV = corrected p value. (A) Volcano plots 
depicting changes induced by TNF at the levels of transcriptome, methylome and 
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active chromatin. (B) Venn diagrams showing overlap of significant deregulations 
either at the level of genes (RNA) / regions (DNA methylation and H3K4 
trimethylation) or at the level of KEGG pathways (RNA), among the three different 
stages of Tg197 disease and treatment with human TNF.  
 
Figure 5 Validation of selected deregulations and comparisons between mouse 
and human data. FC = fold change; PV = corrected p value. (A) Scatter plots showing 
correlation between mouse RNA-seq and qRT-PCR data. (B) Volcano plot depicting 
significantly deregulated genes in human RA SFs in comparison to healthy SFs as 
identified by RNA-seq. (C) Venn diagrams showing overlap between significantly up- 
or down-regulated genes or their respective KEGG pathways in mouse and human 
RNA signatures. Mouse data represent the union of deregulated genes across Tg197 
disease stages. (D) qRT-PCR validations in a panel of genes in human SFs. y axis 
shows ΔCt(gene of interest – HPRT1). * p < 0.05; ** p < 0.01; *** p < 0.001. (E) Venn 
diagrams showing overlap in differentially methylated genes between mouse SFs 
(our data) and the intersection of human SF deregulations reported by two studies 
(9,10).  
 
Supplementary Figure 1 Pathology of Tg197 disease stages. Representative 
photomicrographs of ankle joint sections of wild-type (at 8 weeks; A,B) and arthritic 
mice at three stages of disease: 3 weeks (early; C,D); 8 weeks (established; E,F); and 
11 weeks (late; G,H). Haematoxylin-eosin (left) and toluidine blue (right) staining. 
Error bars = 200 μm. Note that in the early stage there is near absence of pathology; 
in the established stage we observe the histological hallmarks of disease (pannus 
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formation with synovial hyperplasia, inflammatory infiltration and erosions to the 
bone and cartilage); finally, in the late stage, there is total distortion of tissue 
architecture, with extensive bone loss and cartilage destruction and high immune 
cell infiltration. 
 
Supplementary Figure 2 Experimental scheme and sequencing statistics. (A) 
Drawing illustrating experimental set-up of this project. (B) Quality scores attained in 
(1) RNA, (2) MethylCap and (3) H3K4me3 sequencing. (C) Table summarising 
sequencing depth statistics for each biological replicate and sequencing effort.  
 
Supplementary Figure 3 The transcriptional networks of the three disease 
stages, as identified by RNEA. (A) Early; (B) established; (C) late. Colour bar indicates 
node centrality; circle size indicates number of edges from the node, i.e. number of 
targets. The top five genes as ranked by node centrality are named in each network. 
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 Sample 
type Diagnosis Sex 
Age 
(years) 
CRP 
(mg/l) 
Disease 
duration 
(years) 
Treatment 
 
RA RA F 71 17 51 2 cDMARDs, corticosteroid 
RA RA F 54 47 16 1 cDMARD, 1 bDMARD, corticosteroid 
RA RA F 64 <8 7 1 cDMARD, 1 bDMARD 
RA RA F 52 <8 20 2 cDMARDs, corticosteroid 
RA RA M 61 <8 9 1 cDMARD, 1 bDMARD, corticosteroid 
RA RA F 70 26 <1 - 
RA RA M 46 <8 3 - 
Healthy Arthralgia M 23 NA 
Healthy Arthralgia M 44 NA 
Healthy Arthralgia F 49 NA 
Healthy Arthralgia M 42 NA 
Healthy Arthralgia F 38 NA 
Healthy Arthralgia F 46 NA 
Healthy Arthralgia M 34 NA   
 
 
CRP = C-reactive protein; RA = rheumatoid arthritis; F = female, M= male; NA = not 
assessed; cDMARD = conventional disease modifying anti-rheumatic drug, bDMARD = 
biological DMARD. 
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Gene Forward primer Reverse primer 
NOD2 TTCTCCGGGTTGTGAAATGT CTCCTCTGTGCCTGAAAAGC 
MMP3 GGGCTATCAGAGGAAATGAG CACGGTTGGAGGGAAACCTA 
TNFAIP3 AAGGACAGTGGGCCTGAAATC TTCCCCGGTCTCTGTTAACAAG 
LECT1 CCTTATCATCAGGAAGGGGAAAG GTGATCCAGTCTAGGGTCGAA 
WNT16 TCACAGGGGCTTCTCAAAAGA AGGAGGCAATGCCCAACC 
PPARG CGAGAGTCAGCCTTTAACGAAAT ATGGCATCTCTGTGTCAACCA 
SP7 CCCAGCAGCCCCGGA CCCGCCGCCTCAGAAG 
DLK1 CACCTATGGGGCTGAATGCT AGAATCCATTTTGGGGGTTGC 
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